» Articles » PMID: 28487844

Inflammation in Prostatic Hyperplasia and Carcinoma-Basic Scientific Approach

Overview
Journal Front Oncol
Specialty Oncology
Date 2017 May 11
PMID 28487844
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic inflammation is associated with both benign conditions and cancer. Likewise, inflammatory cells are quite common in benign prostatic hyperplasia (BPH) and prostatic tissue harboring cancer. Triggers that activate inflammatory pathways in the prostate remain a subject of argument and are likely to be multifactorial, some of these being bacterial antigens, different chemical irritations, and metabolic disorders. Acute and chronic inflammation in prostate leads to accumulation of immunocompetent cells, mainly T lymphocytes and macrophages, but also neutrophils, eosinophils, and mast cells, depending on the type of offending agent. Inflammatory processes activate hyperproliferative programs resulting in nodules seen in BPH, but are also important in creating suitable microenvironment for cancer growth and progression. Inflammatory cells have mostly been shown to have a protumoral effect such as tumor-associated macrophages, but some cell types such as mast cells have antitumoral effects. This review outlines the recent findings and theories supporting the role of inflammatory responses as drivers of both benign and malignant epithelial processes in the prostate gland.

Citing Articles

A step forward in enhancing the health-promoting properties of whole tomato as a functional food to lower the impact of non-communicable diseases.

Natali P, Piantelli M, Sottini A, Eufemi M, Banfi C, Imberti L Front Nutr. 2025; 12:1519905.

PMID: 39980679 PMC: 11841393. DOI: 10.3389/fnut.2025.1519905.


Prostate Cancer: Emerging Modifiable Risk Factors and Therapeutic Strategies in the Management of Advanced Cancer.

Bossio S, Urlandini L, Perri A, Conforti F, Aversa A, Di Agostino S Life (Basel). 2024; 14(9).

PMID: 39337878 PMC: 11433263. DOI: 10.3390/life14091094.


Extract Alleviates Progression of Benign Prostatic Hyperplasia via Modification of Proliferation, Apoptosis, and Inflammation.

Baek E, Hwang Y, Hong E, Won Y, Kwun H Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204137 PMC: 11357589. DOI: 10.3390/ph17081032.


The Effects of Caloric Restriction on Inflammatory Targets in the Prostates of Aged Rats.

Rago V, Conforti F, La Russa D, Antonucci G, Urlandini L, Lofaro D Int J Mol Sci. 2024; 25(10).

PMID: 38791274 PMC: 11120753. DOI: 10.3390/ijms25105236.


Causal associations of immune cells with benign prostatic hyperplasia: insights from a Mendelian randomization study.

Li T, Zhang Y, Zhou Z, Zhang Y, Song X, Zhou X World J Urol. 2024; 42(1):216.

PMID: 38581575 DOI: 10.1007/s00345-024-04913-6.


References
1.
Vaupel P . Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist. 2008; 13 Suppl 3:21-6. DOI: 10.1634/theoncologist.13-S3-21. View

2.
Steiner G, Newman M, Paikl D, Stix U, Memaran-Dagda N, Lee C . Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate. 2003; 56(3):171-82. DOI: 10.1002/pros.10238. View

3.
Zlotta A, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M . Prevalence of inflammation and benign prostatic hyperplasia on autopsy in Asian and Caucasian men. Eur Urol. 2014; 66(4):619-22. DOI: 10.1016/j.eururo.2014.06.026. View

4.
Bhawal U, Ozaki Y, Nishimura M, Sugiyama M, Sasahira T, Nomura Y . Association of expression of receptor for advanced glycation end products and invasive activity of oral squamous cell carcinoma. Oncology. 2005; 69(3):246-55. DOI: 10.1159/000087910. View

5.
Martinez F, Helming L, Gordon S . Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol. 2008; 27:451-83. DOI: 10.1146/annurev.immunol.021908.132532. View